Belgia - saksa - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

endo ventures - tramadol-hydrochlorid - retardtablette - 300 mg - tramadol-hydrochlorid 300 mg - tramadol

Itävalta - saksa - AGES (Agentur für Gesundheit und Ernährungssicherheit)

endo ventures limited - tramadolhydrochlorid - tramadol

Itävalta - saksa - AGES (Agentur für Gesundheit und Ernährungssicherheit)

endo ventures limited - tramadolhydrochlorid - tramadol

Itävalta - saksa - AGES (Agentur für Gesundheit und Ernährungssicherheit)

endo ventures limited - tramadolhydrochlorid - tramadol

Belgia - saksa - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

endo ventures - testosteron - transdermales gel - 50 mg - testosteron 50 mg - testosterone

Euroopan unioni - saksa - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multiples myelom - antineoplastische mittel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - saksa - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymphom, follikulär - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Euroopan unioni - saksa - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastische mittel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Euroopan unioni - saksa - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiples myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopan unioni - saksa - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiples myelom - antineoplastische mittel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.